Score an Extra 655% with EKSO – Make Your Move Now

We've loved EKSO Bionics for some time now. It's revenue has gone up 80% since we first recommended it. Its exports surged 250% in one year. And Sterne Agee kicked off coverage of the company with a "buy" rating and an initial price target of $1.75 per share. Here's why EKSO should be your next profit play... Tags: bionics industry , bionics market , bionics sector , EKSO , Ekso Bionics stock , EKSO stock , human augmentation stock , Income Plays , OTC: EKSO To get full access to all Money Morning content, click here About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience – for free . Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors. Disclaimer: © 2015 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201. The post Score an Extra 655% with EKSO – Make Your Move Now appeared first on Money Morning - We Make Investing Profitable .